An inactivated Covid-19 vaccine candidate developed by Chinese scientists produced a robust immune response and mild side effects in early stage testing, according to a new study.
The results of the first two phases of trials appeared to show the product – developed by Sinopharm and Wuhan Institute of Biological Products – was safe, but a third phase of testing, which has started, would provide more information, the study’s authors said.
“Although the inactivated vaccine elicited robust antibody responses, whether it could protect individuals against Covid-19 remains unknown,” said the study, which was published in the Journal of American Medical Association on Thursday.
Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China.
It is the first to provide clinical trial data for an inactivated vaccine for Covid 19. Inactivated vaccines consist of virus particles, bacteria or other pathogens that have been grown in culture and then lose disease producing capacity.
The Sinopharm product is one of three Chinese vaccine candidates undergoing phase three clinical trials. The new research was conducted by a team of 30 and partly supported by China National Biotec Group, a unit of Sinopharm.
The trial involved 320 healthy adults, aged 18 to 59. They were given four different kinds of injections – either a placebo, or a low, medium or high dose of the vaccine candidate.
The most common side effects were pain at the site of infection and fever, which occurred in between 6 to 25 per cent of the patients, depending on the different dosages used in the trials.
The study said all of the side effects were mild enough to not require medical treatment.
A total of 29 Covid-19 vaccine candidates are undergoing trials around the world, according to the World Health Organisation.
Two of them were produced by Sinopharm and are undergoing phase three testing in the United Arab Emirates. Trials of other products are ongoing in Japan, Britain, the United States, India and elsewhere.
Chinese pharmaceutical firm CanSino earlier published the results of the first two stages of clinical trials of its vaccine candidate, which uses an adenovirus as a vector.
The final phase of testing involves large numbers of people being tested, with the product closely monitored for safety and efficacy. Phase one involves small trial groups, and phase two slightly larger groups.
Did you know that China supplies 40% of the world’s active pharmaceutical ingredients (API) for drug manufacturing? Learn what other ways local healthcare players are expanding their global footprint from the China Healthcare Report, brought to you by SCMP Research, and get a comprehensive industry review and insights on Covid-19 induced market shifts. Purchase now and get a 30% discount before 30 September 2020. You will also receive access to 6 closed-door webinars led by China healthcare’s most influential C-suite executives.
More from South China Morning Post:
This article Coronavirus: Chinese inactivated vaccine candidate produces immune response, study shows first appeared on South China Morning Post